Gefapixant Citrate action and efficacy mechanism

Gefapixant Citrate (Gefapixant Citrate) is a new drug specifically designed to treat chronic cough. Its main advantage is that it targets the P2X3 receptor rather than relying on a broad-spectrum antitussive mechanism. Chronic cough is often refractory to conventional treatments, primarily due to abnormal sensitivity of the cough nerve reflex. P2X3 receptors are ligand-gated ion channels located on cough-related receptors and are highly sensitive to ATP signals. Overactivation can lead to an exaggerated cough reflex. Gefapixant reduces the excitability of cough nerves by selectively inhibiting P2X3 receptors, thereby reducing the frequency of ineffective coughs and improving patients' quality of life.

The drug exists in the form of citrate, which not only ensures the stability and solubility of the drug, but also optimizes oral bioavailability. Compared with traditional antitussives that suppress the central nervous system of cough, Gefapixant is highly targeted and has relatively controllable side effects, especially in avoiding drowsiness, dependence or respiratory depression caused by central suppression. In vitro and clinical studies have shown that Gefapixant has a significant relieving effect on chronic cough and reduces abnormal discharge of cough receptors through the P2X3 target, which is an important breakthrough in the field of chronic cough treatment.

In addition,Gefapixant was developed with an emphasis on individualized treatment concepts. Since the causes of chronic cough are diverse, including upper airway irritation, neurological cough, and lung diseases, its P2X3-targeting mechanism allows the drug to directly act on nerve-sensitive links to achieve precise symptom intervention. Clinically, Gefapixant can significantly improve patients' quality-of-life indicators such as nighttime cough, limited daytime activities, and impact on social interactions. It is especially suitable for patients who do not respond well to conventional cough suppressants.

In summary, Gefapixen represents a new era in the treatment of chronic cough. By targeting P2X3 receptors, the drug not only relieves symptoms, but also optimizes drug safety and tolerability, providing an effective and precise treatment option for patients with chronic cough. At the same time, the design of its citrate form improves drug stability and oral absorption, providing a reliable basis for clinical application and research in the global market.

Reference materials:https://synapse.patsnap.com